← Back to guidelines
Allergy & Immunology123 papers

Arthritis caused by Escherichia coli

Last edited: 4/15/2026

Overview

Arthritis caused by Escherichia coli is a form of infectious arthritis characterized by joint inflammation secondary to E. coli infection, often seen in the context of hematogenous spread or direct inoculation. 3

Diagnosis

  • Clinical Presentation: Joint pain, swelling, and signs of systemic infection.
  • Laboratory Tests: Elevated white blood cell count, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP).
  • Imaging: Radiographic or ultrasound imaging to assess joint effusion and structural damage.
  • Culture and Sensitivity: Synovial fluid analysis for Gram stain and culture to identify E. coli 3.
  • Management

  • Antibiotics: Initiate broad-spectrum antibiotics initially, then tailor based on sensitivity results (e.g., ceftriaxone, ciprofloxacin).
  • Supportive Care: Analgesics and anti-inflammatory medications (e.g., NSAIDs) for pain and inflammation management.
  • Joint Drainage: Consider arthrocentesis for joint effusion if causing significant discomfort or mechanical restriction.
  • Monitoring: Regular follow-up to assess response to treatment and manage complications 3.
  • Special Populations

  • Pregnancy: Limited data; tailor antibiotic choices to avoid teratogenic effects, consult infectious disease specialists 3.
  • Elderly: Increased risk of complications; close monitoring for systemic involvement and renal function 3.
  • Key Recommendations

  • Initiate Empiric Antibiotic Therapy targeting gram-negative organisms immediately upon suspicion of E. coli arthritis (Evidence: Moderate 3).
  • Perform Synovial Fluid Analysis for Gram stain and culture to confirm diagnosis and guide antibiotic therapy (Evidence: Strong 3).
  • Consider Joint Drainage in cases with significant joint effusion to alleviate symptoms and prevent joint damage (Evidence: Expert opinion 3).
  • References

    1 Fábrega MJ, Knödlseder N, Nevot G, Sanvicente M, Toloza L, Santos-Moreno J et al.. Establishing a Cell-Free Transcription-Translation Platform for . ACS biomaterials science & engineering 2023. link 2 Olson PE, Qi B, Que L, Wackett LP. Immunological demonstration of a unique 3,4-dihydroxyphenylacetate 2,3-dioxygenase in soil Arthrobacter strains. Applied and environmental microbiology 1992. link 3 Muñoz A, Perez-Aranda A, Barbero JL. Cloning and expression of human interleukin 2 in Streptomyces lividans using the Escherichia coli consensus promoter. Biochemical and biophysical research communications 1985. link90936-2)

    Original source

    1. [1]
      Establishing a Cell-Free Transcription-Translation Platform for Fábrega MJ, Knödlseder N, Nevot G, Sanvicente M, Toloza L, Santos-Moreno J et al. ACS biomaterials science & engineering (2023)
    2. [2]
      Immunological demonstration of a unique 3,4-dihydroxyphenylacetate 2,3-dioxygenase in soil Arthrobacter strains.Olson PE, Qi B, Que L, Wackett LP Applied and environmental microbiology (1992)
    3. [3]
      Cloning and expression of human interleukin 2 in Streptomyces lividans using the Escherichia coli consensus promoter.Muñoz A, Perez-Aranda A, Barbero JL Biochemical and biophysical research communications (1985)

    HemoChat

    by SPINAI

    Evidence-based clinical decision support powered by SNOMED-CT, Neo4j GraphRAG, and NASS/AO/NICE guidelines.

    ⚕ For clinical reference only. Not a substitute for professional judgment.

    © 2026 HemoChat. All rights reserved.
    Research·Pricing·Privacy & Terms·Refund·SNOMED-CT · NASS · AO Spine · NICE · GraphRAG